319.64
前日終値:
$319.86
開ける:
$322.32
24時間の取引高:
18,134
Relative Volume:
0.04
時価総額:
$14.37B
収益:
$2.76B
当期純損益:
$1.11B
株価収益率:
14.04
EPS:
22.77
ネットキャッシュフロー:
$898.10M
1週間 パフォーマンス:
+1.48%
1か月 パフォーマンス:
-10.83%
6か月 パフォーマンス:
-11.33%
1年 パフォーマンス:
+30.50%
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
UTHR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
UTHR
United Therapeutics Corp
|
317.97 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
509.94 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
655.00 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
289.23 | 37.54B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ARGX
Argen X Se Adr
|
610.93 | 37.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ONC
Beigene Ltd Adr
|
255.17 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2024-02-12 | アップグレード | Goldman | Sell → Neutral |
2024-02-05 | 開始されました | Leerink Partners | Outperform |
2023-12-08 | 開始されました | Wells Fargo | Overweight |
2022-12-06 | 開始されました | UBS | Buy |
2022-12-05 | 開始されました | Goldman | Sell |
2022-10-11 | 開始されました | Morgan Stanley | Overweight |
2022-09-20 | 繰り返されました | BofA Securities | Underperform |
2022-09-19 | 再開されました | Wedbush | Outperform |
2022-02-11 | 開始されました | BTIG Research | Neutral |
2021-07-14 | アップグレード | Argus | Hold → Buy |
2021-04-26 | 再開されました | Credit Suisse | Outperform |
2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
2020-09-14 | 再開されました | JP Morgan | Overweight |
2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
2020-03-10 | アップグレード | Jefferies | Hold → Buy |
2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
2019-12-03 | 開始されました | BofA/Merrill | Underperform |
2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
2019-05-17 | アップグレード | UBS | Sell → Neutral |
2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
2018-02-22 | 繰り返されました | Barclays | Underweight |
2018-01-18 | 再開されました | Credit Suisse | Underperform |
2017-12-27 | 繰り返されました | Wedbush | Outperform |
2017-04-27 | 繰り返されました | Wedbush | Outperform |
2017-03-30 | 開始されました | UBS | Sell |
2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
United Therapeutics director sells $1.55 million in stock By Investing.com - Investing.com Canada
United Therapeutics director sells $1.55 million in stock - Investing.com India
Market Turbulence? These 20 Stocks Boast a Perfect Piotroski Score and 40%+ Upside - Investing.com
United Therapeutics price target lowered to $314 from $328 at BofA - TipRanks
Exosome Therapy Market Market Is Booming Worldwide 2025-2032 | - openPR
Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
United Therapeutics president Michael Benkowitz sells $640k in stock By Investing.com - Investing.com Australia
For patients needing transplants, hope arrives on tiny hooves - The Spokesman Review
United Therapeutics president Michael Benkowitz sells $640k in stock - Investing.com
What Will United Therapeutics Reveal at the Leerink Conference? Key Details for Investors - StockTitan
Top Executives Cash In on United Therapeutics Stock! - TipRanks
Ray Kurzweil Sells 15,000 Shares of United Therapeutics Corp - GuruFocus.com
United Therapeutics director Thompson sells $795,837 in stock By Investing.com - Investing.com Canada
United Therapeutics director Thompson sells $795,837 in stock - Investing.com India
Silver Spring's United Therapeutics to Begin Clinical Study of Groundbreaking UKidney™ (Pig Organ) Transplant - The MoCoShow
Q2 EPS Estimate for United Therapeutics Lowered by Analyst - Defense World
Oppenheimer Asset Management Inc. Sells 6,988 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Receives FDA Approval for Pig Organ Clinical Trials - Source of the Spring
United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New York State Common Retirement Fund - MarketBeat
Weil Company Inc. Has $449,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
United Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider Selling - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Boosted by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Los Angeles Capital Management LLC Has $36.55 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Truist Financial Corp Sells 2,920 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares - MarketBeat
Atria Wealth Solutions Inc. Invests $412,000 in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
United Therapeutics price target lowered to $420 from $430 at Leerink - Yahoo Finance
Lung transplant technology collaboration between Mayo Clinic Florida and United Therapeutics - Florida Trend
United Therapeutics Corp. Reports Record Revenue and Growth - TipRanks
United Therapeutics Corp. to Host Earnings Call - ACCESS Newswire
United Therapeutics Reports Record Revenue in Q4 2024, Advances Strategic Growth - HPBL
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript - Insider Monkey
Goldman Sachs cuts United Therapeutics stock target to $293 By Investing.com - Investing.com Australia
Goldman Sachs cuts United Therapeutics stock target to $293 - Investing.com
United Therapeutics: Q4 Earnings Snapshot - Thehour.com
United Therapeutics Corp (UTHR) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus.com
United Therapeutics Reports Record 2024 Financial Results - TipRanks
United Therapeutics Enters Oversold Territory (UTHR) - Nasdaq
United Therapeutics (UTHR) Shares Cross Below 200 DMA - Nasdaq
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat - Yahoo Finance
Earnings call transcript: United Therapeutics Q4 2024 earnings miss impacts stock - Investing.com
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations - Yahoo Finance
United Therapeutics: Q4 Earnings Snapshot -February 26, 2025 at 06:49 am EST - Marketscreener.com
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Earnings Flash (UTHR) United Therapeutics Posts Q4 Revenue $735.9M, vs. FactSet Est of $734.7M - Marketscreener.com
UNITED THERAPEUTICS Corp SEC 10-K Report - TradingView
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
PATUSKY CHRISTOPHER | Director |
Mar 19 '25 |
Option Exercise |
175.43 |
5,000 |
877,150 |
5,900 |
PATUSKY CHRISTOPHER | Director |
Mar 19 '25 |
Sale |
310.72 |
5,000 |
1,553,585 |
900 |
大文字化:
|
ボリューム (24 時間):